Opus Genetics (IRD) Reiterated at Market Outperform by Citizens

May 5, 2026 4:21 AM EDT Send to a Friend
Citizens analyst Jonathan Wolleben reiterated a Market Outperform rating and $12.00 price target on Opus Genetics (NASDAQ: IRD).The analyst commented ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login